Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081820 | 1.00 | OPRM1 (0.53) | OPRM1OPRD1OPRK1MAPTNR1H2 | |
| SCHEMBL30470161 | 0.86 | OPRM1 (0.42) | OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL29081285 | 0.86 | OPRM1 (0.42) | OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL24365541 | 0.86 | OPRM1 (0.42) | OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL29081287 | 0.86 | OPRM1 (0.42) | OPRM1OPRD1OPRK1MAPT | |
| SCHEMBL27979493 | 0.76 | OPRM1 (0.52) | OPRM1OPRD1OPRK1MAPTNR1H2 | |
| SCHEMBL29330463 | 0.74 | TP53 (0.41) | OPRM1NR1H2NR1H3TP53MDM2 | |
| SCHEMBL24365249 | 0.73 | MAPT (0.56) | OPRM1OPRD1OPRK1MAPTNR1H2 | |
| SCHEMBL30471064 | 0.72 | MAPT (0.52) | OPRM1OPRD1OPRK1MAPTNR1H2 | |
| SCHEMBL26009111 | 0.71 | ACHE (0.49) | OPRM1OPRK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | OPRM1 286/4885OPRD1 310/4885OPRK1 323/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | OPRM1 286/4885OPRD1 310/4885OPRK1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.